IPP Bureau
Shilpa Medicare aims for US approval of chemo nausea drug
By IPP Bureau - January 09, 2026
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR
By IPP Bureau - January 09, 2026
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
IMCD opens beauty, personal Care laboratory in California
By IPP Bureau - January 09, 2026
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
Alkem launches innovative hair growth support therapy kit
By IPP Bureau - January 09, 2026
The supplements are made using only vegetarian-sourced ingredients
GSK secures European nod for easier-to-use Shingrix prefilled syringe
By IPP Bureau - January 09, 2026
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
GSK reports breakthrough results in chronic hepatitis B trials
By IPP Bureau - January 09, 2026
WHO unveils updated HIV guidelines to boost treatment & save lives
By IPP Bureau - January 09, 2026
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
By IPP Bureau - January 09, 2026
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer
By IPP Bureau - January 09, 2026
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
By IPP Bureau - January 09, 2026
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
World First: Heart bypass without opening the chest achieved by NIH and Emory Team
By IPP Bureau - January 09, 2026
Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug
By IPP Bureau - January 09, 2026
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Newron secures key European patent for schizophrenia drug Evenamide
By IPP Bureau - January 09, 2026
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
By IPP Bureau - January 09, 2026
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids
By IPP Bureau - January 09, 2026
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
